Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.…
Bears are Losing Control Over Cartesian Therapeutics, Inc. (RNAC), Here's Why It's a 'Buy' Now
Cartesian Therapeutics (NASDAQ: RNAC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 75 employees.
The shares were at 6.140 USD on 20 November 2026, down 18.7% over 52 weeks. Its 52-week range is 5.600 USD to 11.00 USD: the price is 44.2% below the high and 9.6% above the low.
Its market capitalisation is 187.29M USD.
Cartesian Therapeutics reports return on equity of 103.2%.
It holds more cash than debt, a net cash position of 62.64M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 8 March 2027.